DexCom, Inc.
http://www.dexcom.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From DexCom, Inc.
No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
Senseonics See Few Barriers To Adoption For Their Implantable CGM
GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.
Insulet Gets A ‘Big Win:’ FDA Clears Omnipod 5 App For iPhone
Insulet’s FDA clearance for its Omnipod 5 App for iPhone will expand its phone-controlled automated insulin delivery system beyond Android users with a full market release in 2024.
Woman In Advanced Therapies: How Diverse Is The Sector Really?
Cell and gene therapy is a young biopharma sector approaching adolescence. As more companies transition from R&D to commercialization, has it got the balance right on diversity in senior leadership?
Company Information
- Industry
-
Medical Devices
- Monitoring Equipment & Devices
-
In Vitro Diagnostics
- Biosensors
- Glucose Testing
- Other Names / Subsidiaries
-
- SweetSpot Diabetes Care
- TypeZero Technologies, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice